Research on the preventive effect of the atrial fibrillation by febuxostat - Research on the preventive effect of the atrial fibrillation by febuxostat

Cardiology, National defense medical college0 个研究点目标入组 60 人开始时间: 2014年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(a) persistent and permanent AF (b) The patient who was new-prescribed in an ACE inhibitor or ARB within six months recently. A patient who had the quantity of an ACE inhibitor or ARB increased within six months. (c) The patient who has mitral stenosis more than the degree of moderate class (d) The patient who received catheter ablation during less than three months or research period. (e) The patient already medicated with allopurinol. (f) A patient with the past of the hypersensitivity to the medicine (g)The patient who has liver disease (AST or ALT >100U) (h)The patient who has a severe renal failure (BUN >30mg/dL, Serum creatinin >2.5mg/dL) (i) The patient under administration of azathioprine, vidarabine and didanosine (contraindications) (j) A woman under pregnancy or with the possibility of pregnancy (k) The woman under breast-feeding (l) The patient who received medication of other trial drugs within three months before the medication (m) In addition, the patient who judged that a chief (assignment) researcher was unsuitable as a subject

发起方

Cardiology, National defense medical college